90560-10-4

Usage

Uses

Used in Organic Synthesis:
6-Methoxybenzo(b)thiophene is used as a key building block in organic synthesis for the creation of various complex organic molecules. Its presence in the molecular structure allows for the formation of diverse chemical entities with potential applications in different fields.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 6-Methoxybenzo(b)thiophene is utilized as a starting material for the synthesis of a wide range of drugs. Its unique structure and biological activities make it a valuable component in the development of new therapeutic agents.
Used in Materials Science:
6-Methoxybenzo(b)thiophene is employed in materials science for the development of organic electronic and optoelectronic devices. Its electronic properties and structural features contribute to the advancement of these technologies, enhancing their performance and potential applications.
Used in Drug Discovery and Development:
6-Methoxybenzo(b)thiophene is used as a starting material for the synthesis of compounds with potential therapeutic applications. Its interesting biological activities make it a promising candidate for drug discovery and development, leading to the creation of new pharmaceuticals with improved efficacy and safety profiles.

InChI:InChI=1/C9H8OS/c1-10-8-3-2-7-4-5-11-9(7)6-8/h2-6H,1H3

Upstream product

• 22546-89-0 6-methoxy-benzothiophene-3-ol 
• 98733-08-5 1-<(2,2-dimethoxyethyl)thio>-3-methoxybenzene 
• 96803-85-9 1-[(2,2-diethoxyethyl)sulfanyl]-3-methoxybenzene 
• 86119-84-8 phosphoric acid 
• 5858-22-0 2,3-dihydro-6-methoxybenzo[b]thiophen-3-one 
• 15570-12-4 3-methoxybenzenethiol 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 7465-86-3 4-methoxy-N,N-diethylbenzamide 
• 596805-19-5 N,N-diethyl-2-methylsulfanyl-4-methoxybenzamide 
• 3996-32-5 [(3-methoxyphenyl)sulfanyl]acetic acid 
• 144-55-8 sodium hydrogencarbonate 
• 331-64-6 2-fluoro-4-methoxy-benzaldehyde 
• 187753-62-4 ethyl 6-methoxybenzo[b]thiophene-2-carboxylate 
• 102539-79-7 6-methoxybenzo[b]thiophene-2-carboxylic acid 

Downstream Products

• 19301-39-4 1-benzothiophen-6-ol 
• 102539-79-7 6-methoxybenzo[b]thiophene-2-carboxylic acid 
• 193964-15-7 6-methoxy-2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzo[b]thiophene 
• 182133-35-3 6-methoxy-benzo[b]thiophen-2-yl boronic acid 
• 98733-09-6 6-methoxybenzothiophene-1,1-dioxide 
• 648906-10-9 2-(4-methanesulfonyl-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thiophen-6-ol 
• 648906-02-9 6-benzyloxy-2,3-dibromo-benzo[b]thiophene 
• 648906-03-0 6-benzyloxy-2,3-dibromo-benzo[b]thiophene 1-oxide 
• 648906-04-1 1-{2-[4-(6-benzyloxy-2-bromo-1-oxo-1H-1λ⁴-benzo[b]thiophen-3-yloxy)-phenoxy]-ethyl}-piperidine 
• 648905-98-0 1-{2-[4-(6-benzyloxy-2-bromo-benzo[b]thiophen-3-yloxy)-phenoxy]-ethyl}-piperidine 
• 946077-41-4 C₃₇H₃₉NO₃S 
• 648906-08-5 C₃₅H₃₅NO₅S₂ 
• 648906-05-2 1-(2-{4-[6-benzyloxy-2-(4-ethanesulfonyl-phenyl)-benzo[b]thiophen-3-yloxy]-phenoxy}-ethyl)-piperidine 
• 648906-06-3 2-(4-ethanesulfonyl-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thiophen-6-ol 

Relevant academic research and scientific papers

Enantioselective hydroarylation or hydroalkenylation of benzo[b]thiophene 1,1-dioxides with organoboranes

An efficient protocol for the asymmetric hydroarylation and hydroalkenylation of benzo[b]thiophene 1,1-dioxides with organoboranes has been developed. The combination of a rhodium(I) precatalyst and a chiral diene ligand constitutes the catalytic system, which enables the facile synthesis of 2,3-dihydrobenzo[b]thiophene 1,1-dioxides in good yields with high enantioselectivities. The merging of this asymmetric hydroarylation with the downstream alkylations delivers 2,3-dihydrobenzo[b]thiophene 1,1-dioxides that contain two continuous quaternary stereocenters with high enantioselectivities in a diastereodivergent manner.

Concise synthesis and biological evaluation of 2-Aryl-3-Anilinobenzo[b]thiophene derivatives as potent apoptosis-inducing agents

Many clinically used agents active in cancer chemotherapy exert their activity through the induction of cell death (apoptosis) by targeting microtubules, altering protein function or inhibiting DNA synthesis. The benzo[b]thiophene scaffold holds a pivotal place as a pharmacophore for the development of anticancer agents, and, in addition, this scaffold has many pharmacological activities. We have developed a flexible method for the construction of a new series of 2-aryl-3-(3,4,5-trimethoxyanilino)-6-methoxybenzo[b]thiophenes as potent antiproliferative agents, giving access to a wide range of substitution patterns at the 2-position of the 6-methoxybenzo[b]thiophene common intermediate. In the present study, all the synthesized compounds retained the 3-(3,4,5-trimethoxyanilino)-6-methoxybenzo[b]thiophene moiety, and the structure–activity relationship was examined by modification of the aryl group at its 2-position with electron-withdrawing (F) or electron-releasing (alkyl and alkoxy) groups. We found that small substituents, such as fluorine or methyl, could be placed in the para-position of the 2-phenyl ring, and these modifications only slightly reduced antiproliferative activity relative to the unsubstituted 2-phenyl analogue. Compounds 3a and 3b, bearing the phenyl and para-fluorophenyl at the 2-position of the 6-methoxybenzo[b]thiophene nucleus, respectively, exhibited the greatest antiproliferative activity among the tested compounds. The treatment of both Caco2 (not metastatic) and HCT-116 (metastatic) colon carcinoma cells with 3a or 3b triggered a significant induction of apoptosis as demonstrated by the increased expression of cleaved-poly(ADP-ribose) polymerase (PARP), receptor-interacting protein (RIP) and caspase-3 proteins. The same effect was not observed with non-transformed colon 841 CoN cells. A potential additional effect during mitosis for 3a in metastatic cells and for 3b in non-metastatic cells was also observed.

Synthesis Development of the Selective Estrogen Receptor Degrader (SERD) LSZ102 from a Suzuki Coupling to a C-H Activation Strategy

The development of the synthetic process to the selective estrogen receptor degrader (SERD) drug candidate LSZ102 from the medicinal chemistry synthesis to the streamlined large-scale manufacturing route is described. The synthesis of LSZ102 could be sign

NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF

The present invention relates to a new compound having an FGFR inhibitory activity and preparation and application thereof. In particular, the compound according to the present invention has a structure as shown in formula I, wherein each group and substituent are as defined in the description. Also disclosed in the present invention are a preparation method for the compound and a use thereof in preparation of a drug for treating and/or preventing a tumor-related disease and/or an FGFR-related disease.

PD-1/PD-L1 small-molecule inhibitor and preparation method and application thereof

The invention discloses a PD-1/PD-L1 small-molecule inhibitor and a preparation method and application thereof. Specifically, the invention discloses a compound with the structure shown in the formulaL, a stereoisomer or a tautomer thereof, or pharmaceutically acceptable salts or hydrates or solvates thereof, and please see the specification for specific definitions. The compound has excellent effects for restraining PD-1/PD-L1. Please see the specification for the formula.

ESTROGEN RECEPTOR-MODULATING COMPOUNDS

Described herein are compounds that are estrogen receptor modulators of formula I' Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

5-Substituted Benzothiophenes: Synthesis, Mechanism, and Kinetic Studies

The kinetics of the reaction of 4-methoxythiophenoxyacetaldehyde diethyl acetal, 4-nitrothiophenoxyacetaldehyde diethyl acetal, and 3-methoxythiophenoxyacetaldehyde diethyl acetal in polyphosphoric acid has been explained. The kinetic behavior has been ex

SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS

The present invention relates to substituted triazolopyridine compounds of general formula (I), in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER

The present invention relates to novel compounds showing an inhibitory effect on Mps-1 kinase, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.